Discgenics treated the first patients in its clinical trial of intervertebral disc tissue for mild to moderate degenerative disc disease in Japan, reports Biospectrum Asia.
Three insights:
1. The double-blinded trial is evaluating the efficacy of IDCT at two dosage levels in participants with single-level symptomatic lumbar degenerative disc disease.
2. IDCT is an allogeneic, non-invasive cell therapy that is injected into the painful disc percutaneously.
3. It uses biomedically engineered progenitor cells — known as discogenic cells — that are derived from intervertebral disc tissue to look for a regenerative solution to degenerative disc disease.